<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Steven Kundrot on Medium]]></title>
        <description><![CDATA[Stories by Steven Kundrot on Medium]]></description>
        <link>https://medium.com/@skundrot?source=rss-e32155fd2a51------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*WovUcwEBfdTbaceACSKuTQ.jpeg</url>
            <title>Stories by Steven Kundrot on Medium</title>
            <link>https://medium.com/@skundrot?source=rss-e32155fd2a51------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Fri, 20 Nov 2026 03:57:01 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@skundrot/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Can Your Wearable Computing Device Revolutionize Clinical Research?]]></title>
            <link>https://medium.com/trinetx/can-your-wearable-computing-device-revolutionize-clinical-research-d884af1596a1?source=rss-e32155fd2a51------2</link>
            <guid isPermaLink="false">https://medium.com/p/d884af1596a1</guid>
            <category><![CDATA[real-world-evidence]]></category>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[clinical-trials]]></category>
            <dc:creator><![CDATA[Steven Kundrot]]></dc:creator>
            <pubDate>Thu, 14 Mar 2019 11:48:39 GMT</pubDate>
            <atom:updated>2019-03-14T11:48:39.875Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*nMEdzAStLFPuVmstwhyA2Q.jpeg" /></figure><h4><em>Merck GHIF and other financial leaders are investing $40 million in TriNetX because they believe it will.</em></h4><p>Tracking steps with a Fitbit, monitoring your heart with an Apple Watch, or tracking blood sugar in real time is helping people improve their health. The information gleaned from wearable devices is one piece of a complex web of critical health data that researchers crave. Wearable data combined with the information found in patient electronic medical records, medical and pharmacy claims data, lab and genomic data, registry data, unstructured clinical data, and patient-reported outcomes–known collectively as Real-World Data (RWD)–is beginning to dramatically transform clinical research.</p><p>The scientific community is striving to collect and analyze more data to improve patient outcomes. RWD leads to Real-World Evidence (RWE) which is key to better development and use of medical products. Leveraging this growing source of data is another giant step in the direction of precision medicine.</p><p>Last Fall, as a result of a mandate from the 21st Century Cures Act, the U.S. Food and Drug Administration <a href="https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm627760.htm">announced</a> a framework designed to leverage RWE to support the development of drugs and biologics. The framework forms a cornerstone of the FDA’s efforts to better leverage RWD and RWE in their regulatory decisions. Even before the release of the framework, the FDA’s decade long Sentinel Initiative for post market surveillance and their more recent clearance of the new Apple Watch 4 for use as a class II medical device are just two of many examples where the agency has embraced the expanded use of RWD.</p><p>RWE can lead to the discovery of new uses for approved pharmaceuticals, help scientists study the safety of medications over longer periods of time, and remove friction and costs from the clinical trial process. RWE, however, is only as good as the RWD that underpins it.</p><p><strong>The Research Bottleneck</strong></p><p>There is still work to be done before RWD translates to better medicine. Today, important RWD is too often collected manually and ported from one siloed database to another in a process that is slow, disjointed, and prone to error. This cumbersome process is slowing the discovery of crucial evidence needed to uncover valuable insights.</p><p>To be meaningful, RWD must first be added to various data-capture systems in order to be analyzed. This is where bottlenecks often occur. Many of these systems lack the analytics to help glean actionable insights from the information, and most data-capture systems are unable to communicate with one another or easily share information. That’s why error-prone, manual data wrangling is the norm and why there is only limited real-time collaboration among researchers.</p><p>The bottleneck doesn’t just slow the pace of biomedical research. It also adds layers of complexity to an already expensive and inefficient system of clinical trials. The <a href="https://www.sciencedirect.com/science/article/abs/pii/S0167629616000291">estimated cost</a> of bringing a new drug to market ranges from $500 million to $2.7 billion per drug and can take up to 10 years to gain approval. Incorporating RWD into the trial process can eliminate costly delays when it comes to selecting sites, finding investigators, and enrolling patients. But RWD can contribute even more than that.</p><p><strong>How Advanced Technology Can Help</strong></p><p>To fuel the clinical research revolution, the healthcare industry must modernize by bringing advanced technologies into the collection and analysis of RWD. The clinical research market sector needs companies that understand and embrace the challenges standing in the way of this critical transformation to reap the benefits of RWE.</p><p>TriNetX is one of those companies. It is the global health research network that revolutionizes clinical research and enables discoveries through the generation of RWE. The efforts of TriNetX to continue this groundbreaking innovation were recently bolstered with the infusion of $40 million in venture capital from new investors Merck GHIF, Mitsui &amp; Co., Ltd., ITOCHU Technology Ventures and ITOCHU Corporation, who join existing investors MPM Capital, F2 Ventures, and Deerfield Management.</p><p>The funding will be used to further develop TriNetX’s industry leading analytics platform, especially in the areas of artificial intelligence, machine learning and digital clinical trials. The investment will aid in the design and execution of traditional randomized trials, pragmatic trials, and observational studies being conducted in the U.S. and internationally.</p><p>Gadi Lachman, our CEO at TriNetX, said it perfectly in our press announcement yesterday: “The landscape for clinical research is changing and TriNetX is leading the disruption as the industry transitions to leveraging data-driven insights to power clinical research and market surveillance. We’ve created the only RWE ecosystem that brings data, analytics and a researcher community together, to aid in the design of randomized or pragmatic clinical trials and support of observational studies, whether retro- or prospective, controlled or longitudinal.”</p><p>TriNetX turns siloed data-capture systems into a network, automating the sharing of data, and adding a layer of analytical tools that convert raw data into useful information. This is providing the missing piece of the puzzle in clinical research today. Since its inception, TriNetX has helped top pharma companies improve their trial design, site selection, and patient identification for recruitment by leveraging RWD through collaboration with a global network of healthcare organizations. More recently, TriNetX has accelerated retrospective analyses on RWD and dramatically decreased the time necessary to analyze and compare outcomes in the real-world. In the near future, TriNetX will release capabilities that support prospective research in an RWD setting. That is just the beginning of TriNetX’s grand vision–the disruption of the RWE market specifically and clinical research in general.</p><p><strong>Enabling Digital Clinical Trials</strong></p><p>Advanced data technologies like TriNetX will remove many of the barriers that medical treatments face on their way to market by ushering in a new era of digital clinical trials. These partially automated trials will generate RWE with far fewer delays and mishaps that cause drug-development costs to skyrocket. TriNetX offers the first clinical research platform that combines RWD in one place with the necessary analytics to streamline and simplify digital trial design and execution.</p><p>Digital clinical trials provide a way to ensure that the largest number of patients can benefit from the medical breakthroughs that should be making all of us healthier. Biomedical researchers are awash in data today, but there are still too many barriers to translating that data into better human health. The best data technologies should be removing those barriers, not adding layers of cost and complexity. TriNetX is helping to tear down these barriers not only through its advanced technology, but also by developing an unprecedented ecosystem encompassing the entire healthcare research community.</p><p>TriNetX’s network of healthcare organizations leverages the strong relationships we’ve curated to further integrate EMR data with electronic data capture (EDC) and patient reported outcomes (PRO) systems used to collect information for prospective studies. Through this integration, we allow the research community to avoid error prone and costly double data entry. This functionality streamlines source data verification, risk-based monitoring activities, and enables researchers to generate early and on-going insights.</p><p>Simplifying data accessibility allows researchers, patients and healthcare organizations to find one another easily, without spending months or years chasing down relevant data. This enables pharma companies and CROs to efficiently design trials for success from the beginning. Researchers can also use the platform to quickly assemble cohorts for retrospective or prospective drug studies, and to share their data with other researchers.</p><p>The new financing ensures that TriNetX will continue this journey to become the go-to resource for clinical research similar to other networks that have achieved dominance in the social and business aspects of our lives.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=d884af1596a1" width="1" height="1" alt=""><hr><p><a href="https://medium.com/trinetx/can-your-wearable-computing-device-revolutionize-clinical-research-d884af1596a1">Can Your Wearable Computing Device Revolutionize Clinical Research?</a> was originally published in <a href="https://medium.com/trinetx">TriNetX</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
    </channel>
</rss>